Formerly known as ApoLife, Inc., BioSavita, Inc. is organized around development of therapeutic antibodies employing a technology platform based on yeast (Saccharomyces cerevisiae) expression systems that accelerate the discovery and development of antibody therapeutics and recombinant proteins. Used in manufacturing various food, beverage, and multiple FDA approved therapeutic products, BioSavita is using Saccharomyces cerevisiae to developsTwin Cassette yeast expression system for biopharma and biotechnology companies to accelerate the process of bringing the new therapies to market; and throughput synthetic DNA technology platform that enables the manufacture of functional antibodies in secreted form. Originally founded by former scientists of Apex Bioscience, Inc., the firm has developed the platform technology, the intellectual property, and the technical know-how to advance and participate in the rapidly expanding market for the therapeutic recombinant proteins, monoclonal antibodies (mAb), next generation antibody scaffolds, and biogeneric products including recombinant vaccines. platform has the capability to make fully functional secreted antibodies and has potential to improve antibody potency. The technology has the capability to accelerate the process of identifying and selecting antibodies for target antigens, reducing the cost and development time by up to 50% of the current process. The firm uses its technology to develop proprietary anticancer antibodies and immunotoxins with collaborating partners. As a licensing partner, the firm canalso provide novel proprietary vectors, yeast strains, and production process available for antibody and biogeneric product development.
